IMvigor 210: Phase 2 trial of atezolizumab, anti-PD-L1, in advanced urothelial carcinoma | Prof Thomas Powles at ECC 2015

At the European Cancer Congress (ECC) 2015, Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of IMvigor 210, a multicentre, phase 2 clinical trial that was designed to evaluate the efficacy and safety of atezolizumab, an anti-PD-L1 antibody, in patients with locally-advanced or metastatic urothelial carcinoma.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews